Ixabepilone Alone or With Cetuximab as First-Line Treatment for Advanced/Metastatic Triple-Negative Breast Cancer

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F15%3A10294561" target="_blank" >RIV/00216208:11130/15:10294561 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064203:_____/15:10294561

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.clbc.2014.07.007" target="_blank" >http://dx.doi.org/10.1016/j.clbc.2014.07.007</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.clbc.2014.07.007" target="_blank" >10.1016/j.clbc.2014.07.007</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Ixabepilone Alone or With Cetuximab as First-Line Treatment for Advanced/Metastatic Triple-Negative Breast Cancer

Popis výsledku v původním jazyce

Efficacy of ixabepilone (n = 40), or ixabepilone with cetuximab (n = 39), as first-line treatment for advanced/metastatic triple-negative breast cancer (TNBC) was assessed. Objective response rates of 30% and 35.9% were observed in the monotherapy and combination arms, respectively. Median progression-free survival was 4.1 months in both arms. Monotherapy and combination therapy demonstrated similar levels of activity, with predictable safety profiles. Background: Despite high initial sensitivity to chemotherapy, TNBC is associated with a poor prognosis, highlighting the need for novel therapeutic strategies. The aim of this multicenter, randomized, open-label phase II trial was to assess the efficacy of ixabepilone as monotherapy, and the combinationof ixabepilone with cetuximab, as first-line treatment in patients with triple-negative locally advanced nonresectable and/or metastatic breast cancer. Patients and Methods: Women were randomly assigned to receive either ixabepilone (40 m

Název v anglickém jazyce

Ixabepilone Alone or With Cetuximab as First-Line Treatment for Advanced/Metastatic Triple-Negative Breast Cancer

Popis výsledku anglicky

Efficacy of ixabepilone (n = 40), or ixabepilone with cetuximab (n = 39), as first-line treatment for advanced/metastatic triple-negative breast cancer (TNBC) was assessed. Objective response rates of 30% and 35.9% were observed in the monotherapy and combination arms, respectively. Median progression-free survival was 4.1 months in both arms. Monotherapy and combination therapy demonstrated similar levels of activity, with predictable safety profiles. Background: Despite high initial sensitivity to chemotherapy, TNBC is associated with a poor prognosis, highlighting the need for novel therapeutic strategies. The aim of this multicenter, randomized, open-label phase II trial was to assess the efficacy of ixabepilone as monotherapy, and the combinationof ixabepilone with cetuximab, as first-line treatment in patients with triple-negative locally advanced nonresectable and/or metastatic breast cancer. Patients and Methods: Women were randomly assigned to receive either ixabepilone (40 m

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Clinical Breast Cancer

ISSN

1526-8209

e-ISSN

—

Svazek periodika

15

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

8

Strana od-do

8-15

Kód UT WoS článku

000348012400002

EID výsledku v databázi Scopus

2-s2.0-84920503993